Tirzepatide → Cholelithiasis — Null result

← All findings ⬇ Download signed audit packet

Ledger entry · null-result

Tirzepatide → Cholelithiasis — Null result

Drug: tirzepatide · AE: Cholelithiasis

Caliper validation of the submitted claim (drug=tirzepatide, AE=Cholelithiasis). BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=1.37, lower CI=1.06)

Disproportionality

PRR: 1.3731742558924345 (95% CI 1.06–1.78)
Yates χ²: 5.411959883289661
Cases (case-drug + AE): n = 57
Verdict: BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=1.37, lower CI=1.06)

Top reactions in cohort

MedDRA PT	n
Cholelithiasis	54
Off label use	13
Pancreatitis	10
Weight decreased	6
Cholecystitis	4
Gallbladder disorder	4
Incorrect dose administered	3
Nausea	3

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: 66e748485ac7483c17f7f1256064d7c307e8f32b